BioSpace News Archive

Lisata Therapeutics, Inc. today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present at the BIO CEO & Investor Conference being held on February 26-27, 2024 at the New York Marriott Marquis in New York City.

Lipella Pharmaceuticals Inc. announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET.

JDRF and Sanofi Canada are announcing a partnership aimed at amplifying awareness around type 1 diabetes, a chronic autoimmune condition, and the role screening could play in the early detection of this disease.

SkinCure Oncology announced the publication of research, “Image guidance improves freedom from recurrence in superficial radiation therapy for non-melanoma skin cancer,” in Advances in Radiation Oncology, a peer-reviewed journal from the American Society for Radiation Oncology.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS).

NextPoint Therapeutics announced today that the first patient has been dosed with NPX887 in a Phase 1 first-in-human clinical trial for the treatment of patients with solid tumors expressing HHLA2/B7-H7, a tumor antigen strongly upregulated in many human tumors independently of PD-L1.

Janux Therapeutics, Inc. today announced it will host a virtual event discussing updated clinical data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 on Monday, February 26th, 2024, at 4:30PM ET.

Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.

Canopus Biopharma Inc. (OTC PINK:CBIA) dba Blue Heaven Coffee Inc. (BHC) proudly announces a monumental leap forward in its retail innovation and expansion efforts.

Tharimmune, Inc announced today the completion of the Company’s Phase 1 clinical trial with TH104.